A recent phase III trial demonstrated that initial therapy with an immuno-agent improves PFS in patients with HR+, HER2- breast cancer. READ MORE
Presenters called for new ways to evaluate the success of novel agents for the treatment of breast cancer.
Patients with early-stage breast cancer often undergo advanced imaging tests despite recommendations against doing so.
Researchers examined the decision-making processes of patients with breast cancer to understand why a procedure that does not improve survival is increasingly being considered.
Research in Review
MRI results after percutaneous biopsy for ductal carcinoma in situ often overestimate the extent of breast cancer, resulting in unnecessary mastectomies.
A bone metastasis model has been created that simulates interactions between metastatic breast cancer cells and bone cells to determine effectiveness of different treatments.
Adding palbociclib to fulvestrant prolongs progression-free survival compared with fulvestrant alone among pre- and post-menopausal women with HR-positive/HER2-negative metastatic breast cancer.
Using body composition metrics to determine dosage of anthracyclines-taxane based chemotherapy for patients with breast cancer can reduce treatment-related toxicity, according to a study published in Clinical Cancer Research.